ABSTRACT
In real life, a significant number of AAA patients reduce the dose of colchicine. The subclinical inflammation rate is higher in these patients. Long-term follow-up results are needed for the risk of amyloidosis.
A total of 114 FMF patients [76 (67%) female and 38 (33%) male] were included in this study. It was determined that the average colchicine dose of 58 (51%) patients was low dose (<1.5 mg/d). The proportion of patients with subclinical inflammation in the low-dose colchicine group was statistically significantly higher than the standard dose colchicine group (34% and 16% respectively, p=0.031).
International severity scoring system score (ISSF) for FMF was calculated to determine the severity of disease in FMF patients admitted to our clinic. FMF patients, those have an ISSF score ≤2, were divided into two groups regarding to their average daily colchicine dose as low dose group (<1.5 mg per/day) and standart dose group (≥1.5 mg per/day).
The initial dose of colchicine recommended for the treatment of familial Mediterranean fever (FMF) is 1-1.5 mg/day in adults. The aim of this study is to identify FMF patients with mild or controlled disease, who can reduce colchicine doses.